Cadila's Dabhasa facility receives Establishment Inspection Report

Cadila Healthcare announced that the company's API manufacturing facility located at Dabhasa, Gujarat has received an Establishment Inspection Report (EIR). The USFDA had conducted an inspection at the facility from 7 to 11 October 2019. The EIR report stated that the classification of the facility is 'No Action Indicated (NAI)'.

Powered by Capital Market - Live News